Tryptamine Therapeutics (AU:TYP) has released an update.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Tryptamine Therapeutics Limited has announced the appointment of Hamish George as the new Chief Financial Officer, bringing his decade-long expertise in finance and commercial experience to the clinical-stage biotech company. George’s previous roles include Director at Bio101 Financial Advisory and CFO for multiple organizations, poised to aid the company’s development of novel psilocybin-based therapies. The company expressed gratitude to former CFO Jim O’Neill for his contributions and smooth transition of responsibilities to George.
For further insights into AU:TYP stock, check out TipRanks’ Stock Analysis page.